Drug Profile
Research programme: antibiotics - Prokaryotics
Alternative Names: Anti-infective drugs - Prokaryotics; Next-generation antibiotics - ProkaryoticsLatest Information Update: 30 Mar 2023
Price :
$50
*
At a glance
- Originator Merck & Co
- Developer Merck & Co; Prokaryotics; University of Florida
- Class Antibacterials; Small molecules
- Mechanism of Action Cell membrane inhibitors; Cell wall inhibitors; WecA protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Methicillin-resistant Staphylococcus aureus infections; Urinary tract infections
- No development reported Gonorrhoea
Most Recent Events
- 04 Nov 2022 Prokaryotics receives R01 grant grant from National Institute of Allergy and Infectious Diseases (NIAID) for antibiotics development in in Gram-negative infections
- 21 Jul 2022 Early research in Urinary tract infections in USA (IV) (Prokaryotics pipeline; July 2022)
- 21 Jul 2022 Early research in Urinary tract infections in USA (PO) (Prokaryotics pipeline; July 2022)